Eidos Therapeutics raises $106M IPO to advance ATTR med by Amirah Al Idrus Wednesday, June 20, 2018 Eidos' $106 million IPO comes on the heels of a $64 million series B and will support phase 2 and phase 3 trials of its TTR amyloidosis drug.
ITeos raises $75M to trial immuno-oncology drugs by Nick Paul Taylor Wednesday, June 20, 2018 The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year.
Sarepta leaps 50% on early data for Duchenne gene therapy by Amirah Al Idrus Tuesday, June 19, 2018 The data, taken from three patients, showed a 38% increase in a muscle protein that boys with DMD usually lack.
All-in-one CAR-T packages therapy and safety in one molecule by Amirah Al Idrus Thursday, June 14, 2018 French biotech Cellectis has devised a form of CAR-T that contains its therapeutic effects with a safeguard in a single molecule.
Pfizer puts neuroscience at heart of new $600M VC fund by Nick Paul Taylor Wednesday, June 6, 2018 Pfizer is setting aside 25% of the money for investments in neuroscience startups, giving it a way to continue participating in the field.
Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown by Nick Paul Taylor Tuesday, June 5, 2018 The results of a phase 3 trial suggest dacomitinib is more effective than its aging rival.
ASCO: X4 Pharma's I-O combo posts 23% ORR in kidney cancer by Amirah Al Idrus Friday, June 1, 2018 X4 Pharma said the 23% objective response rate was "encouraging" as it was observed in third-line patients, a group whose response rate hovers around 10%.
Chutes & Ladders—Former Novartis oncology head jumps to startup by Conor Hale Friday, June 1, 2018 Novartis' ex-oncology head jumps to startup; Axovant poaches Allergan's CMO; and Biogen brings on Pfizer dealmaker.
Cortexyme gathers $76M to fund antibiotic for Alzheimer’s by Conor Hale Thursday, May 31, 2018 Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.
Gilead, Galapagos hit goal in psoriatic arthritis phase 2 by Nick Paul Taylor Thursday, May 31, 2018 The trial linked the JAK1 inhibitor to significant improvements in symptoms, laying the groundwork for further development in psoriatic arthritis.
